IDO2-IN-1

• CAT Number: I042832
• CAS Number: 2803768-09-2
• Molecular Formula: C21H21BrN10O3
• Molecular Weight: 541.36
• Purity: ≥95%
• Synonyms: N-[[1-[2-[[4-[N’-[(3-bromophenyl)methyl]-N-hydroxycarbamimidoyl]-1,2,5-oxadiazol-3-yl]amino]ethyl]triazol-4-yl]methyl]pyridine-2-carboxamide
• IUPAC Name: N-[[1-[2-[[4-[N'-[(3-bromophenyl)methyl]-N-hydroxycarbamimidoyl]-1,2,5-oxadiazol-3-yl]amino]ethyl]triazol-4-yl]methyl]pyridine-2-carboxamide
• InChI: InChI=1S/C21H21BrN10O3/c22-15-5-3-4-14(10-15)11-25-19(28-34)18-20(30-35-29-18)24-8-9-32-13-16(27-31-32)12-26-21(33)17-6-1-2-7-23-17/h1-7,10,13,34H,8-9,11-12H2,(H,24,30)(H,25,28)(H,26,33)
• InChIKey: KIIAYIPXLMATRX-UHFFFAOYSA-N
• SMILES: C1=CC=NC(=C1)C(=O)NCC2=CN(N=N2)CCNC3=NON=C3C(=NCC4=CC(=CC=C4)Br)NO

IDO2-IN-1（Cat No.:I042832）is a small molecule inhibitor designed to target indoleamine 2,3-dioxygenase 2 (IDO2), an enzyme involved in the metabolism of tryptophan and the regulation of immune responses. IDO2 plays a role in immune suppression by generating metabolites that inhibit T-cell activity, contributing to immune tolerance in cancer and autoimmune diseases. By inhibiting IDO2, IDO2-IN-1 aims to enhance immune responses, particularly in cancer immunotherapy. It has shown promise in preclinical studies for boosting anti-tumor immunity and improving the efficacy of cancer treatments, with ongoing research exploring its clinical potential.